BioSpace News Archive

Applied DNA Sciences, Inc. announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for its Linea™ 2.0 COVID-19 Assay and Linea™ Unsupervised At-Home Sample Collection Kit.

Today, Eurofins (Paris:ERF) subsidiary empowerDX has launched PFAS Exposure™ in the United States, the first direct to consumer at-home test to determine levels of PFAS in a person’s blood and measure 47 of the PFAS “forever chemical” compounds.

Melzi Surgical, a surgical device company dedicated to creating innovative technologies that improve patient outcomes while reducing hospital expenses, announced that Reid Rutherford, Co-Founder and CEO will participate in the JTC Virtual Investor 2022 Top Picks Conference on Wednesday, January 26, 2022 at 1:00 PM ET.

Exclusive agreement with Bayer to evaluate MustGrow’s technologies to determine commercial potential.

My Next Health Inc. (“MNH”) is the world’s leading patient-based AI-functional genomic medical analysis company. MNH is improving human health and accelerating the world’s transition to precision medicine.

Centers for Disease Control and Prevention (CDC)-recommended vaccinations for teens and adults continued to lag in 2020 and into the summer of 2021, according to a follow-up claims analysis commissioned by GSK and conducted by Avalere Health, an Inovalon company.

Vaccination is one of the most effective ways to protect the health of Canadians and people around the world. In the fight against COVID-19, it is critical that as many people as possible get vaccinated to help keep themselves and their communities healthy and protect our health care system.

Dentec Safety Specialists Inc. (www.dentecsafety.com), with a Canadian head office and manufacturing facility in Lenexa, KS specializes in PPE and Safety Equipment.

Altasciences is pleased to have been chosen by Virpax® Pharmaceuticals, Inc. (“Virpax”) (NASDAQ:VRPX) to conduct a first-in-human study of Epoladerm™ (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee.

BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2022.